Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

objectief schreef op 18 september 2020 16:37:

[...]

"met verstand van biotech"' kun je beter in de sector gaan werken. Beurshandel houdt zich enkel bezig met koersen.

quote:

ruudje1 schreef op 18 september 2020 16:48:

[...]

Mevrouw, u blijft maar doorgaan he

quote:

fvmetelen schreef op 18 september 2020 15:17:

Waarom zegt Galapagos niet welke uiterste data het bekend word gemaakt, zij moeten dat toch weten!!!!

quote:

moneymaker_BX schreef op 18 september 2020 09:59:

Voor 10 uur groen

quote:

C200 schreef op 18 september 2020 17:36:

Zodan, 185.560 stuks in de eindveiling.

quote:

Wall Street Trader schreef op 18 september 2020 17:30:

[...]

Onno's words were the end of this month.

There are several triggers to recover again and those are probably coming in the next couple of weeks. The upcoming catalysts are very important.

Let's focus on the future and upcoming catalysts!

2020 newsflow

• Filgotinib Anticipated approval decisions for filgotinib in RA:

Europe (probably next week) GLPG is due $75M on approval in the EU.
A decision from Japanese authorities is expected in October.
GLPG is due $30M on approval in Japan.

• PINTA ‘1205 Ph2a IPF (Q4)

• ROCCELLA ‘1972 Ph2b OA (Q4)

1972 received fast track status! Triggering a 60-day opt-in period for Gilead for US rights.

For GLPG1972, Gilead has the option to pay a $250 million fee to license the compound in the United States after the completion of the ongoing Phase 2b study in osteoarthritis. If certain secondary efficacy endpoints are met, Gilead would pay up to an additional $200 million. Following opt in, Galapagos would be eligible to receive up to $550 million in regulatory and commercial milestones.

• TOLEDO (Q4, likely on R&D Day)

A lot of preclinical data will be announced and revealed including the target and pathway of the Toledo compounds.
Start of 5 Phase 2 studies with GLPG3970 with anticipated readout 1H21

Investor Relations slides | August 2020

www.glpg.com/docs/view/5f455cc855420-en

Onno van de Stolpe: We have a fantastic pipeline with a number of potentially blockbuster molecules moving towards the market. The true innovation, based on a unrivaled target discovery platform, has already delivered new mode of actions into late stage clinical trials, and has the promise to address further diseases with high unmet medical needs. The $ ~6 billion cash pile enables us to make the right decisions for the projects, not hindered by funding concerns. This increases the chance of further success. And that combined with the guaranteed 10-year independence as part of the Gilead deal, makes me a strong believer in the potential to grow out into one of the leading biotech companies in the world.

quote:

Egomarinus schreef op 18 september 2020 17:42:

[...]je bedoelt vast 158.560 stuks...

quote:

fvmetelen schreef op 18 september 2020 17:45:

[...]

quote:

Galapapositief schreef op 18 september 2020 17:56:

Kan niet wachten op GLPG1972 na het optimisme van Onno (en Bart).
Die alleen al kan de koers een flink pak hoger zetten mits goed door first in class, fast track en eerste die disease modifying werkt

quote:

Beurskingpin schreef op 18 september 2020 18:08:

[...]

Geen idee waar u dat enthousiasme gehoord heeft? Hij kan moeilijk depressief erover spreken..wilt echt niks zegge over de uitkomst van de resultaten dat is mijn idee..

quote:

Blokhoofd schreef op 18 september 2020 16:41:

"met verstand van biotech"' kun je beter in de sector gaan werken. Beurshandel houdt zich enkel bezig met koersen.

Beurshandel is wat anders dan wekenlang mekkeren.

quote:

moneymaker_BX schreef op 18 september 2020 15:10:

Hoop onzekerheid over de datum...forumleden maken elkaar gek...de dag is nog niet om kan ook nog NAslot USA om iedere belegger gelijk te behandelen....kans op uiterlijk volgende week is wel degelijki aanwezig maar mijn idee is nog steeds VANDAAG
Slot 120,20

quote:

Galapapositief schreef op 18 september 2020 18:26:

[...]
Je bedoelt het stuk waar hij zei dat hij zich meer druk maakte om de secondary endpoints (verbetering dus meer beweging dus meer pijn) dan de primary?
Dat is in mijn ogen positief.

quote:

C200 schreef op 18 september 2020 17:46:

[...]

Nee, 185560